Can Ozempic Be Prescribed for Weight Loss? Exploring the Facts

Last reviewed: June 5, 2026

Last updated: June 5, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Ozempic (semaglutide) is a glucagon-like peptide-1 receptor agonist approved by the FDA specifically for blood sugar control in adults with type 2 diabetes. While the medication has gained attention for its weight-loss effects, the original FDA approval did not include weight management as an official indication. PlexusDx provides access to compounded semaglutide through licensed 503A pharmacies, offering patients a transparent, affordable path to GLP-1 therapy without the brand-name markup or insurance barriers.

The FDA Approval Status of Ozempic for Weight Loss

Ozempic received FDA clearance in 2017 for blood glucose management in type 2 diabetes patients. The approval was based on clinical trials demonstrating that semaglutide reduced HbA1c levels and improved cardiovascular outcomes in diabetic populations. Weight loss was observed as a secondary benefit in these diabetes studies, with participants losing an average of 4–7 pounds over 30 weeks. However, this weight reduction occurred because semaglutide affects hormones that regulate appetite and satiety, not because the drug was designed or tested primarily for obesity treatment.

A separate medication, Wegovy (also semaglutide but at different doses), received FDA approval in 2021 specifically for chronic weight management in adults with obesity or overweight conditions. This distinction means Ozempic carries the diabetes label, while Wegovy carries the weight-loss label—even though the active compound is identical. Off-label prescribing by physicians remains common in clinical practice, but patients should understand that Ozempic's official indication does not list weight loss as an approved use.

How Semaglutide Works for Weight Management

Semaglutide binds to GLP-1 receptors located in the brain, digestive tract, and pancreas. This activation signals fullness to the hypothalamus, reducing hunger drive and food cravings. The medication also slows gastric emptying, meaning food stays in the stomach longer, extending the feeling of satiety between meals. Clinical trial data shows that patients on higher-dose semaglutide (2.4 mg weekly) experience an average weight loss of 15–22% of baseline body weight over 68 weeks when combined with lifestyle modifications.

The PlexusDx Precision Peptide Genetic Test reports on variants that relate to GLP-1 and related signaling pathways. It does not predict your response to semaglutide or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.

Off-Label Prescribing and Clinical Practice Realities

Physicians have legal authority to prescribe FDA-approved medications for indications beyond their labeled use, a practice called off-label prescribing. Many weight-loss clinics and telehealth providers have prescribed Ozempic off-label for obesity management, particularly as demand for GLP-1 therapy surged following media coverage of celebrity weight-loss results. This practice is ethically permissible when the prescriber believes evidence supports efficacy and informs the patient of the off-label status. However, off-label Ozempic prescriptions often come at premium prices because they route through diabetes-focused supply chains designed for insurance billing.

PlexusDx operates differently by offering compounded semaglutide injections from licensed 503A pharmacies, which produce pharmaceutical-grade preparations at transparent, flat monthly rates. Patients receive the same active ingredient without the brand-name premium or insurance requirement. The compounding model allows PlexusDx to serve all 50 states and make GLP-1 therapy accessible to patients who lack insurance coverage or prefer cash-pay options.

PlexusDx Compounded Semaglutide vs. Brand-Name Ozempic

PlexusDx Semaglutide Injection is $189/mo month-to-month (or $149/mo on the 6-month plan) across all dose levels, adhering to the principle that dose increases do not trigger price increases. This pricing model contrasts sharply with traditional pharmacy models, where patients on Ozempic may face escalating copays as their doctor titrates them to higher doses. Compounded semaglutide from 503A facilities meets USP standards for purity, potency, and sterility, ensuring pharmaceutical quality without the brand markup. All medications from PlexusDx are produced by licensed 503A compounding pharmacies, never 503B outsourcing facilities, which provides additional regulatory oversight and traceability.

Patients can pay with HSA or FSA funds when choosing PlexusDx Compounded Semaglutide, adding a tax-advantaged savings layer. No membership fee, no insurance requirement, and no prior authorization delays characterize the PlexusDx experience. For individuals exploring whether semaglutide matches their metabolic profile, PlexusDx also offers the Precision Peptide Genetic Test ($298) to assess individual variations in GIPR, FTO, and MC4R genes—pathways directly linked to GLP-1 response variability.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test ($298) to personalize your protocol from day one.

Frequently Asked Questions

Is Ozempic officially approved by the FDA for weight loss?

No. Ozempic carries an FDA indication for type 2 diabetes only, approved in 2017. Wegovy, a separate semaglutide product, received FDA approval in 2021 for chronic weight management. Physicians may prescribe Ozempic off-label for weight loss, but this use falls outside the official approved indication.

How much weight do people typically lose on semaglutide?

Clinical trials of higher-dose semaglutide (2.4 mg weekly) show average weight loss of 15–22% of baseline body weight over 68 weeks when combined with diet and exercise changes. Results vary based on individual factors, including genetics, adherence, and lifestyle modifications.

Why is PlexusDx Semaglutide more affordable than Ozempic?

PlexusDx sources compounded semaglutide from licensed 503A pharmacies, bypassing brand-name markups and insurance middleman costs. The flat $189/month pricing means dose increases do not trigger higher bills. Patients also avoid insurance requirements, prior authorizations, and membership fees—paying a transparent monthly rate instead.

Are there side effects I should expect from semaglutide injections?

Common side effects include nausea, vomiting, diarrhea, and constipation, typically mild and temporary as the body adjusts. Serious but rare risks include pancreatitis and gallbladder issues. Patients with personal or family history of medullary thyroid cancer should not use GLP-1 medications.

What does the PlexusDx Precision Peptide Genetic Test measure?

No — the Precision Peptide Genetic Test does not predict your response to tirzepatide or any specific medication. It analyzes pathway-level variants (GIPR (rs1800437), FTO (rs9939609), and MC4R (rs17782313)) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.

Related Reading

• Ozempic For Weight Loss 2
• Average Weight Loss On Ozempic
• Weight Loss Drugs Like Ozempic
• Ozempic Weight Loss Before And After Pictures

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.